A Phase III, randomized, open‐label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy
Authors:
Open Access
- 20 May 2014
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 89 (6) , 646-650
Abstract
Iron deficiency anemia (IDA) is the most common form of anemia worldwide. Although oral iron is used as first‐line treatment, many patients are unresponsive to or cannot take oral iron. This Phase III, open‐label, non‐inferiority study compared the efficacy and safety of ferumoxytol, a rapid, injectable intravenous (IV) iron product with low immunological reactivity and minimal detectable free iron, with IV iron sucrose in adults with IDA of any cause. Patients (N = 605) were randomized 2:1 to receive ferumoxytol (n = 406, two doses of 510 mg 5 ± 3 days apart) or iron sucrose (n = 199, five doses of 200 mg on five nonconsecutive days over 14 days) and followed for 5 weeks. Ferumoxytol demonstrated noninferiority to iron sucrose at the primary endpoint, the proportion of patients achieving a hemoglobin increase of ≥2 g dL−1 at any time from Baseline to Week 5 (ferumoxytol, 84.0% [n = 406] vs. iron sucrose, 81.4% [n = 199]), with a noninferiority margin of 15%. Ferumoxytol was superior to iron sucrose (2.7 g dL−1 vs. 2.4 g dL−1) in the mean change in hemoglobin from Baseline to Week 5 (the alternative preplanned primary endpoint) with P = 0.0124. Transferrin saturation, quality‐of‐life measures, and safety outcomes were similar between the two treatment groups. Overall, ferumoxytol demonstrated comparable safety and efficacy to iron sucrose, suggesting that ferumoxytol may be a useful treatment option for patients with IDA in whom oral iron was unsatisfactory or could not be used. Am. J. Hematol. 89:646–650, 2014.Keywords
This publication has 29 references indexed in Scilit:
- FerumoxytolDrugs, 2012
- Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?Journal of Blood Medicine, 2012
- FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel DiseaseGastroenterology, 2011
- Treatment of iron deficiency anemia associated with gastrointestinal tract diseasesWorld Journal of Gastroenterology, 2010
- Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Ferumoxytol for Treating Iron Deficiency Anemia in CKDJournal of the American Society of Nephrology, 2008
- Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trialAlimentary Pharmacology & Therapeutics, 2005
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- GASTRO-INTESTINAL BLEEDING— A MAJOR CAUSE OF IRON DEFICIENCY IN THE ELDERLYAge and Ageing, 1981